Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556964 | 0.85 | KMT2A (0.49) | KMT2AMEN1MAPTEPHX2RAB9A | |
| SCHEMBL3799030 | 0.84 | KMT2A (0.55) | KMT2AMAPTEPHX2NPC1RAB9A | |
| SCHEMBL3829326 | 0.83 | MGLL (0.54) | KMT2AMAPTEPHX2RAB9A | |
| SCHEMBL31548905 | 0.80 | KMT2A (0.46) | KMT2AMEN1MAPTEPHX2RAB9A | |
| SCHEMBL7912741 | 0.80 | KMT2A (0.53) | KMT2AMAPTEPHX2NPC1RAB9A | |
| SCHEMBL29566162 | 0.79 | KMT2A (0.65) | KMT2AMEN1MAPTRXFP1ALOX5 | |
| SCHEMBL30538270 | 0.78 | MGLL (0.44) | KMT2AMEN1EPHX2 | |
| SCHEMBL14656787 | 0.77 | KMT2A (0.60) | KMT2AMEN1EPHX2 | |
| SCHEMBL35211348 | 0.77 | KMT2A (0.62) | KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL6475569 | 0.77 | KMT2A (0.62) | KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812051-B2 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812051-B2 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2006020722-A2 | POLYMER CONJUGATES OF BETA-LAPACHONE AND BETA-LAPACHONE ANALOGS FOR TUMOR TARGETING | ARQULE, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | ARQULE, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | NQO1, KEAP1, DLD | KMT2A 3402/4885MEN1 1542/4885MAPT 2849/4885 |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | QPCT, KEAP1, SLC46A1 | KMT2A 1490/4885MEN1 2075/4885MAPT 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.